Monday, December 19, 2011 3:12:59 PM
The CEO of a company should not let the PPs go to the level that it has, when
there is no apparent reason or justification for doing so.
Surely his claim of secrecy so that other companies do not finds out an attempt
is been made to lease the Hipodromo V centenario racetrack, does not hold water,
because it was CGAQ who let the cat out of the bag in the first place by making
a public announcement of the attempt to do so.
To tell shareholders that feel as if they have been defrauded and simply sell shares
they may have purchased at 0 .60, or 0.50 , etc. , at the ridiculous low PPs that
the stock is now selling for and just take the loss as if they had gambled is not fair
or realistic.
To further have you I.R. representative state to shareholders that a letter of approval
had been received by the company and have them enthusiastically buy more shares,
only to later find out that it was just a letter of acceptance.
The D. R. government response was just a letter written at the request of CGAQ, that
the offer had been received, they further stated that in the event that sometime in the
future the government was going to entertain the leasing, they would do so in a public
bidding and would let CGAQ know.
In other words, Thank you for your application, but we are not at present entertaining
any lease of the racetrack.
there is no apparent reason or justification for doing so.
Surely his claim of secrecy so that other companies do not finds out an attempt
is been made to lease the Hipodromo V centenario racetrack, does not hold water,
because it was CGAQ who let the cat out of the bag in the first place by making
a public announcement of the attempt to do so.
To tell shareholders that feel as if they have been defrauded and simply sell shares
they may have purchased at 0 .60, or 0.50 , etc. , at the ridiculous low PPs that
the stock is now selling for and just take the loss as if they had gambled is not fair
or realistic.
To further have you I.R. representative state to shareholders that a letter of approval
had been received by the company and have them enthusiastically buy more shares,
only to later find out that it was just a letter of acceptance.
The D. R. government response was just a letter written at the request of CGAQ, that
the offer had been received, they further stated that in the event that sometime in the
future the government was going to entertain the leasing, they would do so in a public
bidding and would let CGAQ know.
In other words, Thank you for your application, but we are not at present entertaining
any lease of the racetrack.
Recent BSEM News
- BioStem Technologies to Showcase Innovation and Clinical Evidence at Symposium on Advanced Wound Care Spring 2026 • GlobeNewswire Inc. • 04/08/2026 11:00:00 AM
- BioStem Technologies to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 03/31/2026 08:05:00 PM
- BioStem Technologies Announces the Publication of its Audited Financial Statements for Fiscal Years 2024 and 2025 • GlobeNewswire Inc. • 03/30/2026 11:00:00 AM
- BioStem Technologies Reports Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 03/24/2026 08:05:00 PM
- BioStem Appoints Jodi Ungrodt to Board of Directors as Audit Committee Chair • GlobeNewswire Inc. • 03/23/2026 03:40:56 PM
- BioStem Appoints Jodi Ungrodt to Board of Directors as Audit Committee Chair • GlobeNewswire Inc. • 03/23/2026 11:00:00 AM
- BioStem Technologies to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call on March 24, 2026 • GlobeNewswire Inc. • 03/11/2026 08:05:00 PM
- BioStem Technologies to Present at the 46th Annual TD Cowen Healthcare Conference • GlobeNewswire Inc. • 02/20/2026 12:00:00 PM
- BioStem Technologies Highlights Alignment with FDA’s Openness to Bayesian Statistical Approaches in Clinical Research • GlobeNewswire Inc. • 02/03/2026 09:05:00 PM
- BioStem Technologies Advances Entry into the Acute Wound Care Market with Acquisition of BioTissue Holdings’ Surgical and Wound Care Business • GlobeNewswire Inc. • 01/21/2026 10:30:00 PM
- BioStem Technologies Comments on Withdrawal of CMS CY 2026 Final Medicare Reimbursement Rule for Skin Substitutes • GlobeNewswire Inc. • 01/07/2026 09:05:00 PM
- BioStem Technologies Products Placed on “12-Month Status Quo Period” List in Update to CMS CY 2026 Final Medicare Reimbursement Rule for Skin Substitutes • GlobeNewswire Inc. • 12/18/2025 12:00:00 PM
- BioStem Technologies® to Debut American Amnion™ at the 2025 Desert Foot Multi-Disciplinary Limb Salvage and Wound Care Conference • GlobeNewswire Inc. • 12/10/2025 12:00:00 PM
- BioStem Technologies Expands Product Access in Medicaid • GlobeNewswire Inc. • 11/25/2025 01:59:13 PM
- BioStem Technologies Reports Third Quarter 2025 Financial Results • GlobeNewswire Inc. • 11/13/2025 09:02:00 PM
- BioStem Technologies Announces Filing of Restated Financial Statements • GlobeNewswire Inc. • 11/13/2025 09:01:00 PM
- BioStem Technologies Provides Comments on CMS CY 2026 Final Medicare Reimbursement Rule Changes for Skin Substitutes • GlobeNewswire Inc. • 11/05/2025 09:05:00 PM
- BioStem Technologies Secures Land Purchase at the Research Park at Florida Atlantic University in Boca Raton for Future Headquarters • GlobeNewswire Inc. • 11/05/2025 12:00:00 PM
- BioStem Technologies Reports Positive Top-Line Clinical Results Demonstrating Superior Outcomes with BioRetain® Allograft in Diabetic Foot Ulcers • GlobeNewswire Inc. • 10/31/2025 11:00:00 AM
- BioStem Technologies to Host Third Quarter 2025 Financial Results Conference Call on November 13, 2025 • GlobeNewswire Inc. • 10/30/2025 08:05:00 PM
- BioStem Technologies Appoints KPMG as its Independent Registered Public Accountant • GlobeNewswire Inc. • 10/27/2025 08:15:00 PM
- BioStem Technologies Expands Partnership with the Florida Panthers as a Sponsor for the 13th Season of the “Heroes Among Us” Program • GlobeNewswire Inc. • 10/02/2025 04:00:00 PM
